Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation

Physiologically based pharmacokinetic (PBPK) modeling can provide an effective way to utilize in vitro and in silico based information in modern risk assessment for children and other potentially sensitive populations. In this review, we describe the process of in vitro to in vivo extrapolation (IVIVE) to develop PBPK models for a chemical in different ages in order to predict the target tissue exposure at the age of concern in humans. We present our on-going studies on pyrethroids as a proof of concept to guide the readers through the IVIVE steps using the metabolism data collected either from age-specific liver donors or expressed enzymes in conjunction with enzyme ontogeny information to provide age-appropriate metabolism parameters in the PBPK model in the rat and human, respectively. The approach we present here is readily applicable to not just to other pyrethroids, but also to other environmental chemicals and drugs. Establishment of an in vitro and in silico-based evaluation strategy in conjunction with relevant exposure information in humans is of great importance in risk assessment for potentially vulnerable populations like early ages where the necessary information for decision making is limited.

[1]  Ronald N Hines,et al.  The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.

[2]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[3]  Paul S Price,et al.  Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. , 2011, Regulatory toxicology and pharmacology : RTP.

[4]  Kairui Feng,et al.  The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance , 2013, In Silico Pharmacology.

[5]  S. Khan,et al.  Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies , 2012, Critical reviews in toxicology.

[6]  Miyoung Yoon,et al.  Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. , 2015, Toxicology.

[7]  K Krishnan,et al.  Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. , 2006, Toxicology and applied pharmacology.

[8]  Bas J Blaauboer,et al.  Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations. , 2015, Toxicology.

[9]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[10]  H. Kaneko.  Biotransformation and Enzymes Responsible for Metabolism of Pyrethroids in Mammals , 2012 .

[11]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[12]  P. Potter,et al.  Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. , 2006, Biochemical pharmacology.

[13]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[14]  Rogelio Tornero-Velez,et al.  Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. , 2010, Toxicology and applied pharmacology.

[15]  J. Fisher,et al.  ONTOGENY OF HEPATIC AND PLASMA METABOLISM OF DELTAMETHRIN IN VITRO: ROLE IN AGE-DEPENDENT ACUTE NEUROTOXICITY , 2006, Drug Metabolism and Disposition.

[16]  P. Potter,et al.  Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. , 2007, Toxicology and applied pharmacology.

[17]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[18]  M. DeVito,et al.  Species Differences in the in Vitro Metabolism of Deltamethrin and Esfenvalerate: Differential Oxidative and Hydrolytic Metabolism by Humans and Rats , 2006, Drug Metabolism and Disposition.

[19]  Y. Tan,et al.  Analysis of biomarker utility using a PBPK/PD model for carbaryl , 2014, Front. Pharmacol..

[20]  M. Longnecker,et al.  Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? , 2015, Environment international.

[21]  Rogelio Tornero-Velez,et al.  Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Paul S Price,et al.  Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos. , 2011, Regulatory toxicology and pharmacology : RTP.

[24]  David M. Reif,et al.  Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets. , 2011, Toxicology.

[25]  C. Pope,et al.  Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. , 2005, Regulatory toxicology and pharmacology : RTP.

[26]  H J Clewell,et al.  Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. , 1993, Toxicology letters.

[27]  Jerry L. Campbell,et al.  Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.

[28]  J. Fisher,et al.  Age, dose, and time-dependency of plasma and tissue distribution of deltamethrin in immature rats. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  Yu-Jui Yvonne Wan,et al.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. , 2009, Biochemical pharmacology.

[30]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[31]  L. Reiter,et al.  Age-dependent differences in the susceptibility of rats to deltamethrin. , 1994, Toxicology and applied pharmacology.

[32]  R. Hines,et al.  Ontogeny of human hepatic cytochromes P450 , 2007, Journal of biochemical and molecular toxicology.

[33]  Amin Rostami-Hodjegan,et al.  Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.

[34]  H J Clewell,et al.  Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.

[35]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[36]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[37]  Harvey J. Clewell,et al.  Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry , 2002, Critical reviews in toxicology.

[38]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[39]  R. Judson,et al.  Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.

[40]  Harvey J. Clewell,et al.  Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  Melvin E. Andersen,et al.  Physiologically-Based Pharmacokinetic Modeling* , 1994 .